抗生素課件(英文)-Is-Resistance-Futile_第1頁(yè)
抗生素課件(英文)-Is-Resistance-Futile_第2頁(yè)
抗生素課件(英文)-Is-Resistance-Futile_第3頁(yè)
抗生素課件(英文)-Is-Resistance-Futile_第4頁(yè)
抗生素課件(英文)-Is-Resistance-Futile_第5頁(yè)
已閱讀5頁(yè)，還剩99頁(yè)未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說(shuō)明：本文檔由用戶(hù)提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

IsResistanceFutile?

DonaldELowUniversityofTorontoOntarioAgencyforHealthProtectionandPromotion

IsResistanceFutile?

DonaldAchievementsinPublicHealthControlofinfectiousdiseasesSanitationandHygieneVaccinationAntibioticsAchievementsinPublicHealthC抗生素課件(英文)-Is-Resistance-Futile抗生素課件(英文)-Is-Resistance-FutileMMWR199948(29);621MMWR199948(29);621Antibiotics:theepitomeofa

wonderdrug

Theintroductionofantibioticsinthe1940sconvertedillnessintoastrictlytechnicalproblem:"virtualeliminationofinfectiousdiseaseasasignificantfactorinsociallife."BurnetFM.Naturalhistoryofinfectiousdisease.2nded.Cambridge:CambridgeUniversityPress,1953Antibiotics:theepitomeofaPrevalenceofIsolatesofMultidrug-ResistantGramNegativeRodsRecoveredWithinTheFirst48hAfterAdmissiontotheHospitalPop-VicasandD'AgataCID

2005;40:1792-8.PrevalenceofIsolatesofMult7MRSADeLeoandChambersJCI2009adaptedfromKlevensetal.JAMAI2007MRSADeLeoandChambersJCI2008NewemergingthreatsHospitalsettingCarbapenemases(KPCs)CommunityS.pneumoniaeCommunityAssociatedMRSAFluoroquinoloneresistantE.coliMulti-drugresistantGCNewemergingthreatsHospitalsClinicalCaseA73yoMwithnotravelhxLaparoscopicrightradicalnephrectomyforahypernephromawithpost-oppneumoniaEmpiricallytreatedwithvariousantimicrobialsincludingthecarbapenemsCulturesfoundMDRK.pneumoniae,initiallyreportedasAmpC-andESBL-containingDiedwithpneumoniaandrespiratoryfailureSKrajden,RobertoMelano,andDylanR.PillaiClinicalCaseA73yoMwithnoDrugMIC(mg/mL)CLSIbreakpointsAmpicillin>16RCephalothin>16RCefoxitin>16RTobramycin>8RAmikacin32ICeftriaxone>32RCiprofloxacin>2RMeropenem4SDrugCLSIbreakpointsAmpicillinCarbapenemasesAbilitytohydrolyzepenicillins,

cephalosporins,monobactams,andcarbapenemsResilientagainstinhibitionbyallcommerciallyviable

?-lactamaseinhibitorsCarbapenemasesAbilitytohydrKPC(K.pneumoniaecarbapenemase)KPCsarethemostprevalentofthisgroupofenzymes,foundmostlyontransferableplasmidsinK.

pneumoniaeSubstratehydrolysisspectrumincludes

cephalosporins,suchascefotaxime.KPCshavetransferredtoEnterobacter

spp.andinSalmonellasppKPC(K.pneumoniaecarbapenemaStreptococcuspneumoniaeMostimportantpathogenin

mild-to-moderateRTIs1

Greatestmorbidity2Greatestmortality2Streptococcuspneumoniae1FileTMJr.Lancet.2003;362:1991-2001;2BartlettJG,etal.ClinInfectDis.2000;31:347-382;StreptococcuspneumoniaeMostiPercentageofPenicillinNon-Susceptible

S.pneumoniaeinCanada:1988-2008CanadianBacterialSurveillanceNetwork,Feb2009*OralbreakpointsusedPercentageofPenicillinNMacrolide-ResistantPneumococci:

CanadianBacterialSurveillanceNetwork,1988-2008CanadianBacterialSurveillanceNetwork,Feb2009Macrolide-ResistantPneumococcS.pneumoniaecolonisation:thekeytopneumococcaldiseaseNPcarriage15%<6mosto40%>19mos~10%afterageof10~3%inadultsInvasiveandmucosalinfectioninvolvesNPcolonizationwithconcurrentviralrespiratoryinfectionKadiogluA.,etal.NatRevMicro2008S.pneumoniaecolonisation:thPneumococcal

VaccinesAlthoughthe23-valentvaccineisimmunogenicinadultsandchildrenolderthan5years,youngchildren(<2years)haveaseverelyimpairedantibodyresponsetopolysaccharidevaccinationPPV23426B89V9N1410A18C11A19F12F23F15B117F5207F22F333F19APneumococcal

VaccinesAlthoughIntroductionofpneumococcalvaccines,OntarioOct1996–PPV23programforadultsIncreasedcoveragefrom?2%to35%inadultsIntroductionofpneumococcalvInvasivepneumococcaldisease,elderly

MetropolitanToronto,1995-2000Invasivepneumococcaldisease,Pediatricinvasivepneumococcaldisease

MetropolitanToronto,1995-2000PediatricinvasivepneumococcaPCV7PPV234426B6B89V9V9N141410A18C18C11A19F19F12F23F23F15B117F522F7F33F319APneumococcalvaccinesPCV7PPV234426B6B89V9V9N141410AMMWRFeb2008InvasivePneumococcalDiseaseinChildren5YearsAfterConjugateVaccineIntroduction,1998--2005TheoverallincidenceofIPDamongchildrenaged<5yearsdeclinedfrom99cases/100,000during1998--1999to23cases/100,000in2005MMWRFeb2008InvasivePneumocoIntroductionofpneumococcalvaccines,OntarioOct1996–PPV23programforadultsIncreasedcoveragefrom?2%to35%inadultsDec2001–PCV7licensedGradualincreaseinuseinchildren(toabout1doseperchild,or4dosesfor20%ofchildren)Jan2005–provincialPCV7programNocatch-up;startwithbirthcohortIntroductionofpneumococcalvPediatricinvasivepneumococcaldisease

MetropolitanToronto,1995-2007PediatricinvasivepneumococcaInvasivepneumococcaldisease,elderly

MetropolitanToronto,1995-2001Invasivepneumococcaldisease,RatesofpenicillinandamoxicillinresistanceCanada:1988-2008CanadianBacterialSurveillanceNetwork,March2008RatesofpenicillinandamoxicMostCommonMDRSPNSerotypesVSMostCommonMDRSPNSerotypesV28MostCommonMDRSPNSerotypesP<0.0001P=0.0009P<0.0001P<0.0001VSMostCommonMDRSPNSerotypes29WorldwidePrevalanceofMRSA

AmongS.aureusIsolatesGrundmannHetal.Lancet2006;368:874.WorldwidePrevalanceofMRSA

A30MRSAinCanada,1995-2005Source:CNISPMRSAinCanada,1995-2005Sourc31Community-Associated

MRSASportsparticipantsInmatesincorrectionalfacilitiesMilitaryrecruitsChildrenindaycareNativeAmericans,AlaskanNatives,PacificIslandersMenwhohavesexwithmenHurricaneevacueesinsheltersFoalwatchersRuralcrystalmethamphetamineusersCommunity-Associated

MRSASpor32FirstOutbreaksofCA-MRSAAustralia(1993)UdoEEetal.Geneticanalysisofcommunityisolatesofmethicillin-resistantStaphylococcusaureusinWesternAustralia.J.Hosp.Infect.1993US(1999)CDC.Fourpediatricdeathsfromcommunity-acquiredmethicillin-resistantStaphylococcusaureus—MinnesotaandNorthDakota,MMWR1999Canada(2000)MulveyMRetal.Community-associatedMethicillin-resistantStaphylococcusaureus,CanadaEID2005Worldwide(2000)VandeneschFetal.Community-AcquiredMethicillin-ResistantStaphylococcusaureusCarryingPanton-ValentineLeukocidinGenes:WorldwideEmergenceEID2003FirstOutbreaksofCA-MRSAAust33EmergenceofCA-MRSACanadaSimoreAetal.CanadianNosocomialInfectionSurveillanceProgramCMRSA7(USA400)CMRSA10(USA300)EmergenceofCA-MRSACanadaSim34CurrentTreatmentOptionsforCA-MRSAInfectionMoelleringRCCID2008CurrentTreatmentOptionsfor35Community-acquiredantibioticresistanceinurinaryisolatesfromadultwomeninCanada

15%ofE.coliisolatesfromadultwomenresistanttoTMP-SMXFluoroquinolone-resistantEcoliwas7%10%ofEcoliisolateswerefluoroquinolone-resistantinwomenolderthan65yearsofageMcIsaacWJetal.CanJInfectDisMedMicrobiol.2006Community-acquiredantibiotic36Quinolone-resistantNeisseriagonorrhoeaeinfectionsinOntarioIsolatesreferredtotheOPHLbetween2002and2006FQ-Rincreasedfrom4.0%in2002to27.8%in2006FQ-Rstrainsweremoreresistanttopenicillin(p<0.001);tetracycline(p<0.001)anderythromycin(p<0.001)Allisolatesweresusceptibletocefixime,ceftriaxone,azithromycinandspectinomycinOtaKetal.CanMedAssJInPressQuinolone-resistantNeisseria37ControllingantimicrobialresistanceReducingcolonizationandinfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiControllingantimicrobialresistanceReducinginfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiTheaverageexcessage-specificnumbersofoutpatientvisitsandcoursesofantibioticsper100childrenperyearNeuzilKMetal.NEJM2000TheEffectofInfluenzaonHospitalizations,OutpatientVisits,andCoursesofAntibioticsinChildrenTheaverageexcessage-specifiControllingantimicrobialresistanceReducingcolonizationandinfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiRespiratoryInfectionsarethe#1ReasonforOfficeVisitsSource:VerispanPDDA2004Numberofcommonofficevisits(millions)RespiratoryInfectionsaretheNearlyTwo-thirdsofallOralSolidAntibioticPrescriptionsareforSinusitisandBronchitisSource:SDI,FANDxRx.Basedonalltablets/capsuleantibioticsforthe52weeksendingApril6,2005Telithromycin(Ketek?)isindicatedforacuteexacerbationsofchronicbronchitis,acutebacterialsinusitisandmild-to-moderate

community-acquiredpneumoniaNearlyTwo-thirdsofallOralUsageofantibioticsinEuropevs.pneumococcalpenicillinI/R1997Felminghametal.

JAntimicrobChemother2000;45:191–201Carsetal.Lancet2001;357:1851–185338.532.528.826.7241813.58.90102030405060FranceSpainPortugalBelgiumItalyUKGermanyNetherlandsDDD/1000/dayDI/RSP%**1996dataUsageofantibioticsinEuropeControllingantimicrobialresistanceReducingcolonizationandinfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiMultivariateAnalysisofRiskFactors0123456β-lactamw/in3monthsAlcoholismNoninvasivedisease<5y≥65yOddsRatio

OtherConsiderationsImmunosuppressionIncludingsteroidsMultiplemedical

comorbiditiesExposuretodaycarechildExposuretoanyantibioticClavo-SanchezAJetal.ClinInfectDis.1997;24:1052-1059.HarwellJI,BrownRB.Chest.2000;117:530-541.VanderkooiOGetal.ClinInfectDis.2005;40:1288-1297.

RisksforPenicillinResistance

inPneumococcusMultivariateAnalysisofRiskPrevalenceofErythromycinResistanceAmongPneumococcibyPriorMacrolideUseP=.02P=.004VanderkooiOGetal.ClinInfectDis.2005;40:1288-1297.P<.0010102030405060NoAntibioticErythromycinClarithromycinAzithromycinRateofMacrolideResistanceinInfectingIsolates(%)PrevalenceofErythromycinResRelativeRiskforInfectionWithFluoroquinolone-ResistantPneumococcibyPriorAntibioticUseVanderkooiOGetal.ClinInfectDis.2005;40:1288-1297.02468101214161820NoPriorAntibioticPriorAntibiotic

(notfluoroquinolone)Prior

FluoroquinoloneLevoofloxacinresistant(%)***P<.001RelativeRiskforInfectionWiFluoroquinolonePDProfileFreeAUC/MICLevofloxacin500mgLevofloxacin750mgGemifloxacin320mgMoxifloxacin400mg40(13-21)(24-40)(72-120)ResistancePrevention~AUC/MIC≥100Efficacy~AUC/MIC≥350206080100120140(41-69)MoranG.JEmergMed.2006;30:377-387.

10035FluoroquinolonePDProfileFreeWHOstatement2000Themosteffectivestrategyagainstantibioticresistanceis:“tounequivocallydestroymicrobes”“therebydefeatingresistancebeforeitstarts”WHOOvercomingAntimicrobialResistance,2000WHOstatement2000WHOOvercomiFluoroquinolone-ResistantPneumococci:

CanadianBacterialSurveillanceNetwork,1997-2008CanadianBacterialSurveillanceNetwork,Jan2009%ResistantFluoroquinolone-ResistantPneuResistanceIsn’tFutileResistanceIsn’tFutile

IsResistanceFutile?

DonaldELowUniversityofTorontoOntarioAgencyforHealthProtectionandPromotion

IsResistanceFutile?

DonaldAchievementsinPublicHealthControlofinfectiousdiseasesSanitationandHygieneVaccinationAntibioticsAchievementsinPublicHealthC抗生素課件(英文)-Is-Resistance-Futile抗生素課件(英文)-Is-Resistance-FutileMMWR199948(29);621MMWR199948(29);621Antibiotics:theepitomeofa

wonderdrug

Theintroductionofantibioticsinthe1940sconvertedillnessintoastrictlytechnicalproblem:"virtualeliminationofinfectiousdiseaseasasignificantfactorinsociallife."BurnetFM.Naturalhistoryofinfectiousdisease.2nded.Cambridge:CambridgeUniversityPress,1953Antibiotics:theepitomeofaPrevalenceofIsolatesofMultidrug-ResistantGramNegativeRodsRecoveredWithinTheFirst48hAfterAdmissiontotheHospitalPop-VicasandD'AgataCID

2005;40:1792-8.PrevalenceofIsolatesofMult59MRSADeLeoandChambersJCI2009adaptedfromKlevensetal.JAMAI2007MRSADeLeoandChambersJCI20060NewemergingthreatsHospitalsettingCarbapenemases(KPCs)CommunityS.pneumoniaeCommunityAssociatedMRSAFluoroquinoloneresistantE.coliMulti-drugresistantGCNewemergingthreatsHospitalsClinicalCaseA73yoMwithnotravelhxLaparoscopicrightradicalnephrectomyforahypernephromawithpost-oppneumoniaEmpiricallytreatedwithvariousantimicrobialsincludingthecarbapenemsCulturesfoundMDRK.pneumoniae,initiallyreportedasAmpC-andESBL-containingDiedwithpneumoniaandrespiratoryfailureSKrajden,RobertoMelano,andDylanR.PillaiClinicalCaseA73yoMwithnoDrugMIC(mg/mL)CLSIbreakpointsAmpicillin>16RCephalothin>16RCefoxitin>16RTobramycin>8RAmikacin32ICeftriaxone>32RCiprofloxacin>2RMeropenem4SDrugCLSIbreakpointsAmpicillinCarbapenemasesAbilitytohydrolyzepenicillins,

cephalosporins,monobactams,andcarbapenemsResilientagainstinhibitionbyallcommerciallyviable

?-lactamaseinhibitorsCarbapenemasesAbilitytohydrKPC(K.pneumoniaecarbapenemase)KPCsarethemostprevalentofthisgroupofenzymes,foundmostlyontransferableplasmidsinK.

pneumoniaeSubstratehydrolysisspectrumincludes

cephalosporins,suchascefotaxime.KPCshavetransferredtoEnterobacter

spp.andinSalmonellasppKPC(K.pneumoniaecarbapenemaStreptococcuspneumoniaeMostimportantpathogenin

mild-to-moderateRTIs1

Greatestmorbidity2Greatestmortality2Streptococcuspneumoniae1FileTMJr.Lancet.2003;362:1991-2001;2BartlettJG,etal.ClinInfectDis.2000;31:347-382;StreptococcuspneumoniaeMostiPercentageofPenicillinNon-Susceptible

S.pneumoniaeinCanada:1988-2008CanadianBacterialSurveillanceNetwork,Feb2009*OralbreakpointsusedPercentageofPenicillinNMacrolide-ResistantPneumococci:

CanadianBacterialSurveillanceNetwork,1988-2008CanadianBacterialSurveillanceNetwork,Feb2009Macrolide-ResistantPneumococcS.pneumoniaecolonisation:thekeytopneumococcaldiseaseNPcarriage15%<6mosto40%>19mos~10%afterageof10~3%inadultsInvasiveandmucosalinfectioninvolvesNPcolonizationwithconcurrentviralrespiratoryinfectionKadiogluA.,etal.NatRevMicro2008S.pneumoniaecolonisation:thPneumococcal

VaccinesAlthoughthe23-valentvaccineisimmunogenicinadultsandchildrenolderthan5years,youngchildren(<2years)haveaseverelyimpairedantibodyresponsetopolysaccharidevaccinationPPV23426B89V9N1410A18C11A19F12F23F15B117F5207F22F333F19APneumococcal

VaccinesAlthoughIntroductionofpneumococcalvaccines,OntarioOct1996–PPV23programforadultsIncreasedcoveragefrom?2%to35%inadultsIntroductionofpneumococcalvInvasivepneumococcaldisease,elderly

MetropolitanToronto,1995-2000Invasivepneumococcaldisease,Pediatricinvasivepneumococcaldisease

MetropolitanToronto,1995-2000PediatricinvasivepneumococcaPCV7PPV234426B6B89V9V9N141410A18C18C11A19F19F12F23F23F15B117F522F7F33F319APneumococcalvaccinesPCV7PPV234426B6B89V9V9N141410AMMWRFeb2008InvasivePneumococcalDiseaseinChildren5YearsAfterConjugateVaccineIntroduction,1998--2005TheoverallincidenceofIPDamongchildrenaged<5yearsdeclinedfrom99cases/100,000during1998--1999to23cases/100,000in2005MMWRFeb2008InvasivePneumocoIntroductionofpneumococcalvaccines,OntarioOct1996–PPV23programforadultsIncreasedcoveragefrom?2%to35%inadultsDec2001–PCV7licensedGradualincreaseinuseinchildren(toabout1doseperchild,or4dosesfor20%ofchildren)Jan2005–provincialPCV7programNocatch-up;startwithbirthcohortIntroductionofpneumococcalvPediatricinvasivepneumococcaldisease

MetropolitanToronto,1995-2007PediatricinvasivepneumococcaInvasivepneumococcaldisease,elderly

MetropolitanToronto,1995-2001Invasivepneumococcaldisease,RatesofpenicillinandamoxicillinresistanceCanada:1988-2008CanadianBacterialSurveillanceNetwork,March2008RatesofpenicillinandamoxicMostCommonMDRSPNSerotypesVSMostCommonMDRSPNSerotypesV80MostCommonMDRSPNSerotypesP<0.0001P=0.0009P<0.0001P<0.0001VSMostCommonMDRSPNSerotypes81WorldwidePrevalanceofMRSA

AmongS.aureusIsolatesGrundmannHetal.Lancet2006;368:874.WorldwidePrevalanceofMRSA

A82MRSAinCanada,1995-2005Source:CNISPMRSAinCanada,1995-2005Sourc83Community-Associated

MRSASportsparticipantsInmatesincorrectionalfacilitiesMilitaryrecruitsChildrenindaycareNativeAmericans,AlaskanNatives,PacificIslandersMenwhohavesexwithmenHurricaneevacueesinsheltersFoalwatchersRuralcrystalmethamphetamineusersCommunity-Associated

MRSASpor84FirstOutbreaksofCA-MRSAAustralia(1993)UdoEEetal.Geneticanalysisofcommunityisolatesofmethicillin-resistantStaphylococcusaureusinWesternAustralia.J.Hosp.Infect.1993US(1999)CDC.Fourpediatricdeathsfromcommunity-acquiredmethicillin-resistantStaphylococcusaureus—MinnesotaandNorthDakota,MMWR1999Canada(2000)MulveyMRetal.Community-associatedMethicillin-resistantStaphylococcusaureus,CanadaEID2005Worldwide(2000)VandeneschFetal.Community-AcquiredMethicillin-ResistantStaphylococcusaureusCarryingPanton-ValentineLeukocidinGenes:WorldwideEmergenceEID2003FirstOutbreaksofCA-MRSAAust85EmergenceofCA-MRSACanadaSimoreAetal.CanadianNosocomialInfectionSurveillanceProgramCMRSA7(USA400)CMRSA10(USA300)EmergenceofCA-MRSACanadaSim86CurrentTreatmentOptionsforCA-MRSAInfectionMoelleringRCCID2008CurrentTreatmentOptionsfor87Community-acquiredantibioticresistanceinurinaryisolatesfromadultwomeninCanada

15%ofE.coliisolatesfromadultwomenresistanttoTMP-SMXFluoroquinolone-resistantEcoliwas7%10%ofEcoliisolateswerefluoroquinolone-resistantinwomenolderthan65yearsofageMcIsaacWJetal.CanJInfectDisMedMicrobiol.2006Community-acquiredantibiotic88Quinolone-resistantNeisseriagonorrhoeaeinfectionsinOntarioIsolatesreferredtotheOPHLbetween2002and2006FQ-Rincreasedfrom4.0%in2002to27.8%in2006FQ-Rstrainsweremoreresistanttopenicillin(p<0.001);tetracycline(p<0.001)anderythromycin(p<0.001)Allisolatesweresusceptibletocefixime,ceftriaxone,azithromycinandspectinomycinOtaKetal.CanMedAssJInPressQuinolone-resistantNeisseria89ControllingantimicrobialresistanceReducingcolonizationandinfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiControllingantimicrobialresistanceReducinginfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiTheaverageexcessage-specificnumbersofoutpatientvisitsandcoursesofantibioticsper100childrenperyearNeuzilKMetal.NEJM2000TheEffectofInfluenzaonHospitalizations,OutpatientVisits,andCoursesofAntibioticsinChildrenTheaverageexcessage-specifiControllingantimicrobialresistanceReducingcolonizationandinfectionReducingvolumeofantimicrobialuseWhendecisionmadetotreatUserightdrugRightdoseRightdurationControllingantimicrobialresiRespiratoryInfectionsarethe#1ReasonforOfficeVisitsSource:VerispanPDDA2004Numberofcommonofficevisits(millions)RespiratoryInfectionsaretheNearlyTwo-thirdsofallOralSolidAntibioticPrescriptionsareforSinusitisandBronchitisSource:SDI,FANDxRx.Basedonalltablets/capsuleantibioticsforthe52weeksendingApril6,2005Telithromycin(Ketek?)isindicatedforacuteexacerbationsofchronicbronchitis,acutebacterialsinusitisandmild-to-moderate

community-acquiredpneumoniaNearlyTwo-thirdsofallOralUsageofantibioticsinEuropevs.pneumococcalpenicillinI/R1997Felminghametal.

JAntimicrobChemother2000;45:191–201Carsetal.Lancet2001;357:1851–185338.532.528.826.7241813.58.90102030405060FranceSpa

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽，若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間，僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請(qǐng)與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論